摘要
目的探讨帕罗西汀联合氯丙嗪治疗精神分裂症的临床疗效及安全性。方法选取医院2016年4月至2018年5月收治的精神分裂症患者82例,按治疗方式不同分为观察组与对照组,各41例。对照组患者给予氯丙嗪治疗,观察组患者在对照组基础上联合帕罗西汀治疗,两组均治疗8周。结果观察组临床总有效率为95.12%,明显高于对照组的70.73%(P<0.05);治疗后,两组阳性与阴性症状量表评分均明显下降,且观察组明显低于对照组(P<0.05);治疗后,两组汉密尔顿抑郁量表评分均明显下降,且观察组明显低于对照组(P<0.05);观察组并发症发生率为21.95%,与对照组的19.51%相当(P>0.05)。结论与单用氯丙嗪相比,帕罗西汀联合氯丙嗪可提高精神分裂症的整体临床疗效,改善患者阴性症状与减轻抑郁程度,且安全性较好。
Objective To investigate the clinical efficacy and safety of paroxetine combined with chlorpromazine in the treatment of schizophrenia.Methods Totally 82 patients with schizophrenia admitted to our hospital from April 2016 to May 2018 were selected and divided into the observation group and the control group according to different treatment methods,41 cases in each group.The patients in the control group were treated with chlorpromazine,while the patients in the observation group were treated with paroxetine on the basis of the control group.Both groups were treated for 8 weeks.Results The total clinical effective rate of the observation group was 95.12%,which was significantly higher than 70.73% of the control group(P<0.05).After treatment,the scores of positive and negative symptom scale in the two groups were significantly decreased,and those in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the score of Hamilton Depression Scale(HAMD) in the two groups was significantly decreased,and that in the observation group was significantly lower than that in the control group(P<0.05).The incidence of complications in the control group was 21.95%,which was similar to 19.51% in the control group(P>0.05).Conclusion Compared with chlorpromazine alone,paroxetine combined with chlorpromazine can improve the overall clinical efficacy in the treatment of patients with schizophrenia,can significantly improve the negative symptoms and reduce the degree of depression,and it has better safety.
作者
徐勇
蒋志锋
何泽民
胡庭刚
XU Yong;JIANG Zhifeng;HE Zemin;HU Tinggang(The Third People′s Hospital of Panzhihua,Panzhihua,Sichuan,China 617061;Renhe District People′s Hospital of Panzhihua,Panzhihua,Sichuan,China 617061)
出处
《中国药业》
CAS
2019年第23期43-45,共3页
China Pharmaceuticals
基金
四川省卫生和计划生育委员会科研项目[16PJ212]
